Compare ARMOUR Residential REIT, Inc. (ARR) vs Cassava Sciences Inc (FLNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARMOUR Residential REIT, Inc. vs Cassava Sciences Inc — how do they compare? ARMOUR Residential REIT, Inc. trades at $16.88 (market cap $2.11B), while Cassava Sciences Inc trades at $1.17 (market cap $57.49M). The key difference: ARMOUR Residential REIT, Inc. is far larger — about 36.7× Cassava Sciences Inc's market cap, and ARMOUR Residential REIT, Inc. pays a 16.89% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| ARR | FLNA | |
|---|---|---|
Market Cap | $2.11B | $57.49M |
Sector | Financials | Health |
52-Week High | $19.12 | $4.64 |
52-Week Low | $14.05 | $1.16 |
Dividend Yield | 16.89% | — |
Enterprise Value | — | -$29.09M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARR trades at $17.05, down 0.23% today, with a neutral technical signal and bullish moving averages. The stock shows a low P/E of 6.85 and P/B of 0.9, indicating potential undervaluation, while recent earnings beat expectations in Q1 2026. Dividend payments remain steady at $0.24 per share, supporting income appeal. Revenue for 2025 was $332M with a net income margin of 97.2%, though cash flow trends show volatility in investing activities.
Outlook is mixed: analyst consensus is a $18.50 price target with 20% buy ratings, but risks include volatile earnings and high cash flow swings. The stock offers value and yield, yet requires caution due to operational inconsistencies and market sentiment leaning hold.
FLNA trades at $1.18, down 0.84% today, with a bearish technical signal from moving averages. The company shows negative profitability with ROE at -79.59% and ROA at -62.5%, though it has beaten EPS estimates for three consecutive quarters. Recent news highlights Q1 2026 financial results and scientific presentations on TSC-related epilepsy therapies. Analyst consensus remains positive with 67% buy ratings.
While analyst sentiment is bullish, FLNA faces significant fundamental challenges with negative cash flow and earnings. The primary investment opportunity lies in successful drug development, but risks include sustained cash burn and clinical trial outcomes. Investors should weigh the high-risk biotech profile against potential pipeline catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ARMOUR Residential REIT, Inc.
ARMOUR Residential REIT Inc is a real estate investment trust that invests in residential mortgage-backed securities or RMBS. These are issued or guaranteed by U.S.-government-sponsored enterprises, such as Fannie Mae, Freddie Mac, or Ginnie Mae. The company's investment portfolio is composed of mortgage-backed securities, adjustable-rate mortgage securities, and multifamily mortgage-backed securities. In terms of total fair value, most Armour's investments are long-term, fixed-rate agency RMBS. Multifamily RMBS also represents a substantial amount. Fannie Mae guarantees most of the company's holdings. Armour derives substantially all its revenue as interest income from its investments.
Read more on ARR →About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →
